Standard BioTools Inc. Payments to Acquire Debt Securities, Available-for-sale
Standard BioTools Inc. (LAB) reported Payments to Acquire Debt Securities, Available-for-sale of $60.54 million for the 9-month period ending 2011-09-30, per its 10-Q filed 2011-11-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2011-11-14
- Standard BioTools Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2011-09-30 was $2.83M.
- Standard BioTools Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2010-09-30 was $0.00.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month |
|---|---|---|---|
| 2011-09-30 | $2.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $60.54M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $57.71M 10-Q · filed 2011-08-09 | ||
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $0.00 10-Q · filed 2011-11-14 | |
| 2010-06-30 | $0.00 10-Q · filed 2011-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |